Results 41 to 50 of about 4,026 (142)

Auxiliary Liver Graft Can Be Protected From HBV Infection in HBsAg Positive Blood Circulation

open access: yesFrontiers in Medicine, 2021
Auxiliary grafts have a high risk of Hepatitis B virus (HBV) infection in patients with chronic HBV-related diseases. Hepatitis B virus-related auxiliary partial orthotopic liver transplantation (APOLT) cases were reviewed to show the results of current ...
Lin Wei   +22 more
doaj   +1 more source

Recompensation of Cirrhosis: A New Treatment‐Related Disease State

open access: yesPortal Hypertension &Cirrhosis, EarlyView.
This perspective article conceptualizes recompensation of cirrhosis as a distinct treatment‐related disease state rather than mere transient clinical improvement after etiology‐directed therapy, and further proposes a four‐state classification including compensated cirrhosis, stable recompensation, unstable recompensation, and persistent decompensation
Wentao Tan   +5 more
wiley   +1 more source

A case of gynecomastia due to entecavir.

open access: yes, 2010
Hepatitis B is an important health problem all over the world as well as in our country. Entecavir is a nucleoside analog used in the treatment of chronic hepatitis B.
Dabak, Resat   +9 more
core   +1 more source

The Emerging Role of China in the Innovation, Individualization, and Translation of Antiviral Therapeutics for Chronic Hepatitis B

open access: yesPortal Hypertension &Cirrhosis, EarlyView.
This perspective outlines China's contributions toward functional‐cure‐oriented antiviral therapies for chronic hepatitis B, summarizing key clinical data on bepirovirsen and domestic drug pipelines with balanced coverage of both promising and disappointing trial results.
Dandan Weng, Zhujun Cao, Qing Xie
wiley   +1 more source

Release mechanism and pharmacodynamics of entecavir micro spheres

open access: yesPakistan Journal of Pharmaceutical Sciences
Entecavir, an effective anti-hepatitis B drug with low resistance rate, was designed as sustained-release micro spheres in our previous study. Here, we aimed to reveal the drug-release mechanism by observing the drug distribution and degradation behavior
Chunyan Zhang   +3 more
doaj   +1 more source

Effectiveness and Safety of Vunakizumab Over 12 Weeks in Chinese Patients With Plaque Psoriasis: A Prospective, Real‐World Cohort Study

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Vunakizumab is a humanized anti‐IL‐17A monoclonal antibody approved in China for moderate‐to‐severe plaque psoriasis. Real‐world data on its effectiveness and predictors of response remain scarce. This prospective, single‐center, observational study enrolled 34 adults receiving vunakizumab (240 mg subcutaneously at weeks 0, 2, and 4, then ...
Tong Wu   +4 more
wiley   +1 more source

Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.: Mechanism of entecavir resistance

open access: yes, 2007
International audienceBACKGROUND/AIMS: Complex mutants may be selected under sequential anti-VHB pressures. We analyzed the genotypic and phenotypic evolution of the viral quasi-species of a patient who developed resistance to entecavir following ...
Christian Trépo   +13 more
core   +1 more source

The Impact of Common Medications on Male Fertility: An Updated Systematic Review

open access: yesAndrology, EarlyView.
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli   +7 more
wiley   +1 more source

Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients

open access: yesJournal of the Formosan Medical Association, 2014
Several anti-viral drugs are approved for the treatment of hepatitis B virus (HBV) infection. However, whether quantitative hepatitis B surface antigen (qHBsAg) can predict the therapeutic response during long-term entecavir treatment remains unclear ...
Chia-Chi Wang   +4 more
doaj   +1 more source

Carriage of the Laboratory of Genetics and Physiology Protein 2 Q425R Variant Reduces Liver Disease Severity in European Patients With Chronic Hepatitis Delta

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
In patients with chronic hepatitis Delta, the LGP2 Q425R variant (rs2074158 CC/CT genotypes), associated with an enhanced interferon response in vitro, becomes progressively less frequent as liver disease advances from no cirrhosis to cirrhosis, and to cirrhosis with progressive increase of portal hypertension evaluated by thrombocytopenia.
Sara Cmet   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy